ArticleBMC women's health2026
Early predictive value of calcification on ultrasound and mammography for pathological complete response to neoadjuvant chemotherapy in breast cancer.
Article in BMC women's health, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
3 authors.
Funding
Abstract
objectiveThis study aimed to evaluate early predictors of pathological complete response (pCR) to neoadjuvant chemotherapy (NAC) in breast cancer and analyze tumor regression factors by integrating clinicopathological and imaging features.
methodsWe retrospectively analyzed the clinical data from 149 breast cancer patients who received neoadjuvant chemotherapy (NAC) at our hospital between January 2021 and January 2023, dividing them into pCR (61) and non-pCR (88) groups. Student’s t-test, chi-square test, multivariate logistic regression, and ROC curve analysis assessed pCR-associated factors and the predictive value of ultrasound-mammography combinations.
resultsSignificant group differences (P < 0.05) emerged in imaging features (ultrasound/mammographic calcification characteristics) and clinicopathological markers (clinical stage, T3 status, HER2, Ki67, EGFR). Multivariate analysis identified independent pCR predictors: ultrasound-detected calcifications (OR = 0.07), mammographic grouped calcifications (OR = 0.12), T3 stage (OR = 0.02), and HER2 − /EGFR + status (OR = 0.14), all linked to lower pCR rates. Combined ultrasound-mammography calcification analysis showed a larger AUC (area under ROC curve) than single-modality assessments.
conclusionsPretreatment ultrasound calcifications, mammographic grouped calcifications, advanced T stage, HER2 negativity, and EGFR positivity correlate with reduced pCR after NAC, indicating poorer prognosis. Ultrasound-mammography combination demonstrates high predictive value for pCR assessment, enhancing NAC response evaluation in breast cancer.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.